COLORECTAL CANCER IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A SINGLE-CENTRE EXPERIENCE.

Roberto Citarrella, Domenico Sinagra, Monica La Spada, Giovanni Tomasello, Francesco Cappello, Gaetano Cristian Morreale, Valentina Guarnotta, Angelo Leone, Massimo Midiri, Fania Puccia, Federico Midiri, Filippo Mocciaro, Roberto Di Mitri, Salvatore Marasa', Serena Dolcimascolo

Risultato della ricerca: Article

1 Citazione (Scopus)

Abstract

type 2 diabetes mellitus (T2DM) is associated with an increased risk of colorectal cancer (CRC). The aim of the study is to evaluate the prevalence of CRC in a cohort of caucasian patients with T2DM and the association with other variables previously known to be related with increased risk of CRC, We retrospectively evaluated the data of 741 consecutive Caucasian patients with T2DM who underwent colonscopic screening in our tertuary refererral center. A control cohort of 333 patients with thyroid disease was selected to evaluate the difference in the incidence of CRC. at a median follow-up of 132,5 months (range 33,3-175,7), 67 cases of cancer (prevalence 9%) occured; among these, 14 cases of were reported (prevalence 1,88%) among the diabetic partients, while only two caase (one of this was a CRC) (owerall prevalence 0,0006%) prevalence of CRC 0,003) occurred in the control group; the difference between the prevalence of CRC was statistically significant (chi-square 4,21, p=0,04). The median duration of T2DM to CRC diagnosis was 168 months 8range 12-768). At the univariate analysis, older age (p=0,001, r 0,138) and diabetes duration (p=0,0001, r 0,138) were related to higher risk of cancer, while metformin seems to be protective towards cancer (p=0,07, r-0,098). In the subset of patients with CRC, the age (RR=2,25; 95% CI: 0,30-17,31; p< 0,001), the diabtees duration (RR=1,93; 95% CI0,25-14,77; p=0,001) and the sulphonylureas treatment (RR=2,33; 95% CI 0.78-7,38; p = 0,007) were independently correlated with CRC. In our study, the prevalence of CRC in a cohort of patients with T2DM was higher compared to that from the national Tumor Register in 2010 (0,5%). Furthermore, we could speculate that sulphonylureas may play a role in CRC carcinogenesis impairing the physiological insulin secretion.
Lingua originaleEnglish
pagine (da-a)1101-1107
Numero di pagine7
RivistaDefault journal
Volume4
Stato di pubblicazionePublished - 2017

Fingerprint

Type 2 Diabetes Mellitus
Colorectal Neoplasms
Neoplasms
Metformin
Thyroid Diseases
Carcinogenesis
Insulin
Control Groups

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Physiology
  • Immunology
  • Oncology
  • Endocrinology
  • Physiology (medical)
  • Cancer Research

Cita questo

@article{f62172eb8c8c4fcb9a0442cafc4b7279,
title = "COLORECTAL CANCER IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A SINGLE-CENTRE EXPERIENCE.",
abstract = "type 2 diabetes mellitus (T2DM) is associated with an increased risk of colorectal cancer (CRC). The aim of the study is to evaluate the prevalence of CRC in a cohort of caucasian patients with T2DM and the association with other variables previously known to be related with increased risk of CRC, We retrospectively evaluated the data of 741 consecutive Caucasian patients with T2DM who underwent colonscopic screening in our tertuary refererral center. A control cohort of 333 patients with thyroid disease was selected to evaluate the difference in the incidence of CRC. at a median follow-up of 132,5 months (range 33,3-175,7), 67 cases of cancer (prevalence 9{\%}) occured; among these, 14 cases of were reported (prevalence 1,88{\%}) among the diabetic partients, while only two caase (one of this was a CRC) (owerall prevalence 0,0006{\%}) prevalence of CRC 0,003) occurred in the control group; the difference between the prevalence of CRC was statistically significant (chi-square 4,21, p=0,04). The median duration of T2DM to CRC diagnosis was 168 months 8range 12-768). At the univariate analysis, older age (p=0,001, r 0,138) and diabetes duration (p=0,0001, r 0,138) were related to higher risk of cancer, while metformin seems to be protective towards cancer (p=0,07, r-0,098). In the subset of patients with CRC, the age (RR=2,25; 95{\%} CI: 0,30-17,31; p< 0,001), the diabtees duration (RR=1,93; 95{\%} CI0,25-14,77; p=0,001) and the sulphonylureas treatment (RR=2,33; 95{\%} CI 0.78-7,38; p = 0,007) were independently correlated with CRC. In our study, the prevalence of CRC in a cohort of patients with T2DM was higher compared to that from the national Tumor Register in 2010 (0,5{\%}). Furthermore, we could speculate that sulphonylureas may play a role in CRC carcinogenesis impairing the physiological insulin secretion.",
author = "Roberto Citarrella and Domenico Sinagra and {La Spada}, Monica and Giovanni Tomasello and Francesco Cappello and Morreale, {Gaetano Cristian} and Valentina Guarnotta and Angelo Leone and Massimo Midiri and Fania Puccia and Federico Midiri and Filippo Mocciaro and {Di Mitri}, Roberto and Salvatore Marasa' and Serena Dolcimascolo",
year = "2017",
language = "English",
volume = "4",
pages = "1101--1107",
journal = "Default journal",

}

TY - JOUR

T1 - COLORECTAL CANCER IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A SINGLE-CENTRE EXPERIENCE.

AU - Citarrella, Roberto

AU - Sinagra, Domenico

AU - La Spada, Monica

AU - Tomasello, Giovanni

AU - Cappello, Francesco

AU - Morreale, Gaetano Cristian

AU - Guarnotta, Valentina

AU - Leone, Angelo

AU - Midiri, Massimo

AU - Puccia, Fania

AU - Midiri, Federico

AU - Mocciaro, Filippo

AU - Di Mitri, Roberto

AU - Marasa', Salvatore

AU - Dolcimascolo, Serena

PY - 2017

Y1 - 2017

N2 - type 2 diabetes mellitus (T2DM) is associated with an increased risk of colorectal cancer (CRC). The aim of the study is to evaluate the prevalence of CRC in a cohort of caucasian patients with T2DM and the association with other variables previously known to be related with increased risk of CRC, We retrospectively evaluated the data of 741 consecutive Caucasian patients with T2DM who underwent colonscopic screening in our tertuary refererral center. A control cohort of 333 patients with thyroid disease was selected to evaluate the difference in the incidence of CRC. at a median follow-up of 132,5 months (range 33,3-175,7), 67 cases of cancer (prevalence 9%) occured; among these, 14 cases of were reported (prevalence 1,88%) among the diabetic partients, while only two caase (one of this was a CRC) (owerall prevalence 0,0006%) prevalence of CRC 0,003) occurred in the control group; the difference between the prevalence of CRC was statistically significant (chi-square 4,21, p=0,04). The median duration of T2DM to CRC diagnosis was 168 months 8range 12-768). At the univariate analysis, older age (p=0,001, r 0,138) and diabetes duration (p=0,0001, r 0,138) were related to higher risk of cancer, while metformin seems to be protective towards cancer (p=0,07, r-0,098). In the subset of patients with CRC, the age (RR=2,25; 95% CI: 0,30-17,31; p< 0,001), the diabtees duration (RR=1,93; 95% CI0,25-14,77; p=0,001) and the sulphonylureas treatment (RR=2,33; 95% CI 0.78-7,38; p = 0,007) were independently correlated with CRC. In our study, the prevalence of CRC in a cohort of patients with T2DM was higher compared to that from the national Tumor Register in 2010 (0,5%). Furthermore, we could speculate that sulphonylureas may play a role in CRC carcinogenesis impairing the physiological insulin secretion.

AB - type 2 diabetes mellitus (T2DM) is associated with an increased risk of colorectal cancer (CRC). The aim of the study is to evaluate the prevalence of CRC in a cohort of caucasian patients with T2DM and the association with other variables previously known to be related with increased risk of CRC, We retrospectively evaluated the data of 741 consecutive Caucasian patients with T2DM who underwent colonscopic screening in our tertuary refererral center. A control cohort of 333 patients with thyroid disease was selected to evaluate the difference in the incidence of CRC. at a median follow-up of 132,5 months (range 33,3-175,7), 67 cases of cancer (prevalence 9%) occured; among these, 14 cases of were reported (prevalence 1,88%) among the diabetic partients, while only two caase (one of this was a CRC) (owerall prevalence 0,0006%) prevalence of CRC 0,003) occurred in the control group; the difference between the prevalence of CRC was statistically significant (chi-square 4,21, p=0,04). The median duration of T2DM to CRC diagnosis was 168 months 8range 12-768). At the univariate analysis, older age (p=0,001, r 0,138) and diabetes duration (p=0,0001, r 0,138) were related to higher risk of cancer, while metformin seems to be protective towards cancer (p=0,07, r-0,098). In the subset of patients with CRC, the age (RR=2,25; 95% CI: 0,30-17,31; p< 0,001), the diabtees duration (RR=1,93; 95% CI0,25-14,77; p=0,001) and the sulphonylureas treatment (RR=2,33; 95% CI 0.78-7,38; p = 0,007) were independently correlated with CRC. In our study, the prevalence of CRC in a cohort of patients with T2DM was higher compared to that from the national Tumor Register in 2010 (0,5%). Furthermore, we could speculate that sulphonylureas may play a role in CRC carcinogenesis impairing the physiological insulin secretion.

UR - http://hdl.handle.net/10447/278320

M3 - Article

VL - 4

SP - 1101

EP - 1107

JO - Default journal

JF - Default journal

ER -